Group 1: Technology Sector Insights - At CES 2026, AMD and Intel presented their AI strategies, with AMD's stock dropping approximately 3% and Intel's rising about 2% due to differing product announcements [2] - Nvidia's CEO highlighted the Rubin platform, which includes six core chips, and emphasized the transition from Physical AI to Agentic AI, with expected shipments in the second half of 2026 [3] - The focus for AI investments in 2026 is shifting towards real-time response capabilities and the penetration of AI in various verticals such as industrial and medical applications [2][3] Group 2: Pharmaceutical Sector Insights - The Hong Kong innovative drug sector is expected to recover due to improved liquidity and multiple catalysts, with a focus on the upcoming JPM conference and data disclosure peaks [5] - The decline in innovative drug valuations in late 2025 was primarily due to liquidity issues, which are anticipated to improve in early 2026 [5] Group 3: Consumer Electronics Insights - The CES 2026 showcased a rapid shift of AI and robotics technologies towards consumer hardware, indicating significant product launches in smart home applications [6] - The event is viewed as a critical observation point for AI applications in consumer markets, suggesting investment opportunities in tech consumer companies [6] Group 4: Industrial Equipment Insights - The valve industry is experiencing growth driven by demand from high-growth sectors like energy and new energy, with a notable shift towards domestic production capabilities [8] - The combination of demand growth, technological upgrades, and accelerated localization is reshaping the competitive landscape of the valve industry [8] Group 5: Chemical Sector Insights - Xinhengcheng is recognized as a leading player in the global nutrition and flavor industry, with a focus on emerging demands and a strong technological foundation [10] - The company is expected to enter a new growth cycle, driven by increased market share in methionine and flavor products, alongside advancements in biomanufacturing [10] Group 6: Circular Economy Insights - Wanwu Xinxing is positioned as a leader in the second-hand circular economy, integrating the entire 3C recycling industry chain to enhance efficiency and cost barriers [11] - The company aims to evolve from a service provider to a brand, leveraging retail and compliance refurbishment to increase profit margins [11] Group 7: Financial Sector Insights - GF Securities plans to raise over HKD 6 billion through H-share placement and zero-interest convertible bonds to strengthen its capital base for international expansion [12][13] - Successful fundraising is expected to enhance the company's operational performance and industry ranking [13] Group 8: Electric Vehicle Insights - Yadea Holdings anticipates a significant profit increase for 2025, driven by rising sales of electric two-wheelers and product optimization [14] - The company is expected to maintain its leadership position in the two-wheeler market while expanding into mid-to-high-end and overseas markets [14] Group 9: Semiconductor Sector Insights - Huahong Semiconductor is set to acquire a majority stake in Huali Micro, which is expected to significantly enhance its earnings and liquidity [15] - The acquisition is projected to increase the company's net profit from CNY 380 million to CNY 960 million, marking a 151% growth [15]

步入2026年的3个交易日里，A股持续走强，在半导体、有色板块集体上涨的势头中，此 前一度"沉寂"的创新药板块也再度亮眼，其中港股创新药板块更为出色；此外叠加"脑机 接口"的风潮，有公募认为此前沉寂数年的医疗器械板块或也迎来投资机遇。 展望后市，"普涨"已不再是基金经理的共识，而具备业绩验证的优质个股或将走出持续性的 独立行情；此外，因具备更好的研发和盈利前景，出海能力也成为多名基金经理筛选公司的 核心标准之一。 但像去年上半年的普涨行情或难以再现，诺安精选价值基金经理唐晨表示，2025年我们经历 了从"中国资产重估"到"创新药BD锚定"的主升浪，2026年更应把注意力放在"兑现"上。唐晨 认为，市场可能不会再现全面单边普涨，但真正的好资产会走出更高质量、更强持续性的独 立行情，这对专业投资者反而更友好。 "脑机接口"或带火医疗器械 值得注意的是，近几个交易日内"脑机接口"概念异军突起，消息面上，马斯克在社交媒体表 示，Neuralink预计在2026年开始量产，或预示着脑机接口商业化元年的到来。从新能源车 到人形机器人，再到商业航天，马斯克的商业版图给投资者带来不少的机会，脑机接口的未 来空间同样广阔。 永 ...

Group 1 - The core viewpoint is that the Hong Kong Stock Connect innovative drug sector is experiencing a rebound, with the ETF (520880) showing a 2% increase and breaking above the 60-day moving average, indicating a potential reversal trend as of January 8 [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Select Index has undergone a significant adjustment, with a decline of over 24% since early September 2025, suggesting that the current period may be an optimal time for medium to long-term investment in core innovative drug assets [1] - The long-term logic of pharmaceutical innovation remains unchanged, with the recent positive market performance signaling good opportunities for innovative drugs and medical devices in 2026 [1] Group 2 - The Hong Kong Stock Connect innovative drug ETF (520880) and its associated off-market fund (025221) present a low-entry window, characterized by three unique advantages: purity and comprehensiveness, significant representation of leading companies, and better risk control through forced de-weighting of less liquid stocks [2] - The top ten innovative drug leaders account for over 73% of the index, highlighting the strength of the innovative drug sector [2] - The focus for 2026 will likely remain on "innovation + internationalization," with an emphasis on innovative drugs that show positive industry trends and increasing global competitiveness [1][2]

Core Viewpoint - The Hong Kong stock market continues to adjust, but the innovative drug sector is experiencing a rally, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising for the fourth consecutive day, gaining over 2% and surpassing the 60-day moving average [1][3]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) opened high and rose by 2.02% to a price of 0.555, with a trading volume of 95,100 shares [2]. - Major constituents of the ETF include: - InnoCare Pharma-B (映恩生物-B) up over 6% - Hutchison China MediTech (和黄医药) up over 4% [1][2]. Group 2: Regulatory and Company Developments - The National Medical Products Administration (NMPA) has optimized the review and approval process for innovative drugs, encouraging the application of urgently needed overseas marketed original and generic drugs in China [1][3]. - Recent announcements from innovative drug companies include: - Sinopharm's SAL0145 injection clinical trial application accepted by NMPA [3]. - Hengrui Medicine's approval for its innovative drug Rilapladib injection [3]. Group 3: Investment Sentiment and Recommendations - Recent reports from securities firms such as Pacific Securities, Guotai Junan, and Industrial Securities are bullish on the innovative drug sector, emphasizing the importance of "innovation + internationalization" as a core theme for the pharmaceutical sector by 2026 [3][4]. - The Hong Kong Stock Connect Innovative Drug ETF (520880) tracks the Hang Seng Stock Connect Innovative Drug Select Index, which has three key advantages: 1. Pure and comprehensive coverage of innovative drug R&D companies [4]. 2. High concentration of leading companies, with the top ten innovative drug leaders accounting for over 73% of the index [5]. 3. Controlled risks through forced de-weighting of less liquid constituent stocks [4].

Core Viewpoint - The Hong Kong stock market continues to adjust, but the innovative drug sector is experiencing a rally, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising for the fourth consecutive day, gaining over 2% and surpassing the 60-day moving average [1][3]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) opened high and rose by 2.02%, reaching a price of 0.555 [2]. - Major components of the ETF, such as InnoCare Pharma-B and Hutchison China MediTech, saw significant gains of over 6% and 4%, respectively [1][3]. Group 2: Regulatory Environment - The National Medical Products Administration (NMPA) has optimized the review and approval process for innovative drugs, encouraging the application of urgently needed foreign-origin original and generic drugs in China [1][3]. Group 3: Company Developments - Recent announcements from innovative drug companies include the acceptance of clinical trial applications for SAL0145 injection by Sinopharm and the approval of the innovative drug Rilapladib by Hengrui Medicine [3]. - Securities firms are increasingly optimistic about the innovative drug sector, with reports from Pacific Securities, Guotai Junan, and Industrial Securities recommending continued focus on the innovative drug and medical device industry chain [3]. Group 4: ETF Characteristics - The Hong Kong Stock Connect Innovative Drug ETF (520880) tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has three unique advantages: it is purely focused on innovative drugs, has a high concentration of leading companies, and effectively controls risks associated with less liquid stocks [3][4]. - The top ten holdings in the ETF account for over 73% of its weight, highlighting the dominance of leading innovative drug companies [5].

Group 1 - The core viewpoint of the news highlights significant achievements in the innovation drug sector, with a record 76 innovative drugs expected to be approved for market in China by 2025, marking a historical high [1] - The healthcare payment system is continuously optimized, with the introduction of a "commercial insurance innovative drug directory" mechanism, which enhances the payment capacity for innovative drugs through the complementary combination of medical insurance and commercial insurance [1] - Institutions are optimistic about the pharmaceutical and biotechnology industry, with Donghai Securities predicting that China will officially enter a new era of innovative drugs by 2026 [1] Group 2 - The Hong Kong Stock Connect Innovative Drug ETF managed by Harvest (520970) tracks the CSI Hong Kong Stock Connect Innovative Drug Index, with the top ten weighted stocks including WuXi Biologics, Innovent Biologics, BeiGene, and others, accounting for over 71.80% of the total weight [2] - The management and custody fees for the Harvest Hong Kong Stock Connect Innovative Drug ETF are 0.60% per year, making it suitable for both ordinary investors as a long-term allocation tool and professional investors for flexible trading needs [2]

Group 1 - The Hong Kong stock market continues to adjust, but the innovative drug sector is experiencing gains, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising for the fourth consecutive day, up 2% and surpassing the 60-day moving average [1][8] - Major components of the ETF include companies like InnoCare Pharma-B, which rose over 6%, and Hutchison China MediTech, which increased by over 4% [1][8] - The National Medical Products Administration (NMPA) has optimized the review and approval process for innovative drugs, encouraging the application of urgently needed foreign-origin drugs and generics in China [1][10] Group 2 - Recent announcements from innovative drug companies include the acceptance of clinical trial applications for SAL0145 injection by Sinopharm and the approval of the innovative drug Ruilafup α injection by Hengrui Medicine [3][10] - Securities firms are increasingly optimistic about the innovative drug sector, with reports from Pacific Securities, Guotai Junan, and Industrial Securities recommending continued focus on the innovative drug and medical device industry chain [3][10] - The Hong Kong Stock Connect Innovative Drug ETF (520880) tracks the Hang Seng Stock Connect Innovative Drug Select Index, which has three unique advantages: it is purely focused on innovative drugs, has a high concentration of leading companies, and offers better risk control by reducing the weight of less liquid stocks [3][10] Group 3 - The top ten holdings in the Hong Kong Stock Connect Innovative Drug ETF account for over 73% of the total weight, indicating a strong presence of leading companies in the innovative drug sector [4][11] - Notable companies in the ETF include Kangfang Biologics (10.49% weight), BeiGene (10.01%), and CSPC Pharmaceutical Group (9.97%), among others, with a total market capitalization of approximately HKD 11.35 billion [4][11] - For investors looking to reduce volatility while still focusing on innovative drugs, the market offers the only pharmaceutical ETF (562050) that combines innovative drugs with traditional Chinese medicine, providing a more stable investment option [4][12]

Core Viewpoint - The Hong Kong stock market for innovative drugs has experienced a rally since the beginning of 2026, driven by positive clinical data from Arrowhead, which has boosted sentiment in the sector [1]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (159570) has shown strong performance, with a nearly 2% increase and a trading volume exceeding 9 billion, indicating high trading activity [6]. - As of January 7, 2026, the ETF's latest scale has surpassed 24.7 billion, leading its peers in the same category [6]. - The majority of the weighted stocks in the ETF index have shown positive performance, with notable increases from companies like Sanofi and Innovent Biologics [2]. Group 2: Company News - Strong Brain Technology, a brain-computer interface "unicorn," has completed a financing round of 2 billion, second only to Musk's Neuralink [1]. - Insilico Medicine, an AI-driven pharmaceutical company, has announced a long-term collaboration with Sihuan Pharmaceutical for anti-tumor drug development, with a total cooperation amount of 888 million [1]. Group 3: Industry Trends - The innovative drug industry is expected to continue its upward trend, with catalysts on the horizon. The market anticipates a busy period for business development (BD) transactions and data disclosures in early 2026 [4]. - The upcoming J.P. Morgan Healthcare Conference is expected to attract over 8,000 global participants, showcasing advancements in biotechnology, pharmaceuticals, and medical devices [5]. - Three major trends are emerging in the industry: the continued rise of gene and cell therapies, deep integration of AI in pharmaceuticals, and the rise of emerging market players [7]. Group 4: Investment Insights - The average total package for top multinational corporations (MNCs) purchasing innovative drugs or technology platforms from China in 2025 is 2.756 billion, indicating a willingness to pay higher prices for Chinese innovations [8]. - The focus of MNCs is shifting from merely acquiring products to obtaining platforms and time, emphasizing the importance of technology platforms that can produce new molecules [10]. - Investment logic suggests that MNCs are willing to pay premiums for clinically validated assets, particularly those that can fill pipeline gaps and provide immediate revenue [11].

Core Viewpoint - The pharmaceutical sector, particularly in innovative drugs, is experiencing a surge driven by significant clinical data in the small RNA weight loss field, leading to a notable increase in the STAR Market's innovative drug index and the corresponding ETF [1][3]. Group 1: Small RNA Weight Loss Data - Arrowhead Pharmaceuticals presented mid-stage data from its two small RNA weight loss projects, ARO-INHBE and ARO-ALK7, indicating a new paradigm in "high-quality weight loss" that focuses on visceral fat reduction rather than just weight loss [3][4]. - ARO-INHBE demonstrated a 9.4% weight loss in type 2 diabetes patients when combined with tirzepatide, significantly outperforming tirzepatide alone, which achieved a 4.8% reduction. Key metrics showed visceral fat reduction of 23.2%, total fat reduction of 15.4%, and liver fat reduction of 76.7%, approximately three times better than monotherapy [3][4]. - ARO-ALK7, the first RNAi therapy to validate fat cell gene knockdown effects in humans, achieved an average knockdown of 88% of ALK7 mRNA, with a maximum of 94%. After eight weeks of a single dose, visceral fat decreased by 14.1%, confirming the feasibility of targeting fat cell metabolic pathways [3][4]. Group 2: Significance of Visceral Fat Reduction - The ultimate goal of weight loss treatment is not merely the reduction of weight but the improvement of long-term cardiovascular, renal, and metabolic outcomes. Visceral fat, despite its low absolute quantity, is crucial as it surrounds vital organs and is linked to insulin resistance, fatty liver, and cardiovascular diseases [4]. - Effective reduction of visceral fat could significantly enhance metabolic status and lower the risk of long-term cardiovascular and renal events, providing higher clinical value for managing diabetes, obesity, and related complications [4]. Group 3: Synergy of Small RNA and GLP-1 - Current GLP-1 drugs are foundational in weight loss treatment but have unmet needs regarding visceral fat improvement, muscle loss, and rebound weight gain. The data suggests that small RNA drugs could complement fat metabolism pathways, enhancing the quality of weight loss rather than just the quantity [5]. - This validation of the synergistic logic between small RNA and GLP-1 strengthens market perception of the long-term value of the small RNA technology platform, leading to increased investment in high-research, innovative assets within the STAR Market [5]. Group 4: Future Outlook - The year 2026 is anticipated to be pivotal for small RNA drugs, with significant growth and validation expected, including commercial progress for Plozasiran and larger sample data readouts for ARO-INHBE and ARO-ALK7 [6]. - The capital market may see small RNA companies listing on the Hong Kong stock exchange, further enhancing market focus on this niche sector as overseas RNAi technology matures and domestic pipelines advance [6]. Group 5: Investment Opportunities - Following a period of adjustment, the innovative drug sector's overall valuation has returned to historically low levels. With the upcoming release of high-quality data and international conference catalysts, funds may begin reallocating towards high-elasticity sectors with medium to long-term industrial logic [7]. - Investors are encouraged to monitor developments in high-quality clinical data and international business development progress, which could drive further capital back into the innovative drug sector, potentially leading to a phase of upward trends [8].

Market Overview - The A-share market opened lower with the Shanghai Composite Index down 0.20%, the Shenzhen Component down 0.42%, and the ChiNext Index down 0.63% [2][3] - Over 3,000 stocks declined in the market, with sectors such as brokerage, insurance, retail, and CPO experiencing significant drops [1] Sector Performance - The electronic gas sector saw a strong opening, with Sanfu Co. and Heyuan Gas hitting the daily limit up, while Jin Hong Gas, Huate Gas, Silane Technology, and Yake Technology also showed notable gains [1] - The brain-computer interface concept remained active, with companies like Prit and Innovation Medical achieving four consecutive trading limit ups [1] Notable Stocks - Zhongke Lanyun opened over 12% higher, projecting a net profit increase of 367%-377% year-on-year for 2025 [3] - Yijing Optoelectronics approached the daily limit down, announcing an expected negative net profit for the year 2025 [5] Hong Kong Market - The Hong Kong stock market opened lower, with the Hang Seng Index down 0.59% and the Hang Seng Tech Index down 0.44% [5][6] - Major stocks such as Tencent Music, Baidu Group, Alibaba, and Zijin Mining experienced significant declines, while China Shenhua, China Telecom, and China Merchants Bank showed strength [5]